Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes

Kunihiro Suzuki, Masaaki Sagara, Chie Aoki, Seiichi Tanaka and Yoshimasa Aso

Abstract

Objective The goal of the present study was to investigate the plasma hydrogen sulfide (H₂S) levels in patients with type 2 diabetes, as the plasma H₂S levels in Japanese patients with type 2 diabetes remain unclear.

Methods The plasma H₂S levels were measured in 154 outpatients with type 2 diabetes and 66 outpatients without diabetes. All blood samples were collected in the outpatient department from 09:00 to 10:00. The patients had fasted from 21:00 the previous evening and had not consumed alcohol or caffeine or smoked until sample collection. The plasma H₂S levels were measured using the methylene blue assay. The plasma H₂S levels were determined in triplicate, and the average concentrations were calculated against a calibration curve of sodium sulfide.

Results The patients with type 2 diabetes showed a progressive reduction in the plasma H₂S levels (45.1±15.5 μM versus 54.0±26.4 μM, p<0.05), which paralleled poor glycemic control. There was a significant correlation between a reduction in the plasma H₂S levels and the HbA1c levels (β=-0.505, p<0.01). Furthermore, a reduction in the plasma H₂S levels was found to be related to a history of cardiovascular diseases in patients with type 2 diabetes (39.9±13.8 μM versus 47.5±15.9 μM, p<0.01).

Conclusion Collectively, the plasma H₂S levels were reduced in patients with type 2 diabetes, which may have implications in the pathophysiology of cardiovascular disease in diabetic patients. The trial was registered with the University Hospital Medical Information Network (UMIN no. #000020549).

Key words: hydrogen sulfide, type 2 diabetes, cardiovascular disease

(Intern Med 56: 17-21, 2017)
(DOI: 10.2169/internalmedicine.56.7403)

Introduction

Hydrogen sulfide (H₂S) is a colorless, watersoluble gas with a smell of rotten eggs and is an endogenously produced labile diffusible mediator with multiple roles in the cardiovascular system in health and disease. H₂S is endogenously generated, and cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) are key enzymes involved in its biological production (1-3). Although the physiological effect of H₂S is not yet clear, it is known to influence cardiovascular homoeostasis, such as through vasodilation, pro-apoptotic activities in vascular smooth muscle, leukocyte-endothelium interaction, and suppression of oxidative stress (3-6). We previously reported that, in hyperglycemic endothelial cells and streptozotocin-induced diabetes in rats, hyperglycemia is associated with increased H₂S degradation, as the H₂S concentrations in the media and plasma were decreased. In addition, H₂S replacement relieved oxidative stress and improved the endothelial metabolic states. Brancalone et al. demonstrated that vascular dilation, H₂S biosynthesis, and H₂S endogenous production progressively contribute to the severity of diabetes in non-obese diabetic mice (7). However, little has been reported on plasma H₂S levels in type 2 diabetic patients, particularly Japanese patients.

In the present study, we examined the plasma H₂S levels in patients with type 2 diabetes and evaluated the relevance of H₂S to the history of cardiovascular disease in these patients.
**Materials and Methods**

This randomized pilot study was conducted on 200 randomly selected patients with type 2 diabetes from the 626 outpatients who had visited this institution for type 2 diabetes and 100 without diabetes from the 308 outpatients who had visited for hypertension, dyslipidemia, or thyroid disease controlled satisfactorily by medication. The exclusion criteria were 1) severe ketosis and diabetic coma, 2) severe complication of diabetes, 3) renal insufficiency (serum creatinine level >1.5 mg/dL in men or >1.3 mg/dL in women) and liver dysfunction, 4) severe infection, 5) pregnant or nursing women and those who might be pregnant, 6) alcoholism, and 7) any patients whom the investigators judged to be inappropriate for this study. Ultimately, 154 patients with type 2 diabetes and 66 without diabetes were enrolled.

All of the blood and samples were collected in the outpatient department from 09:00 to 10:00. The patients had fasted from 21:00 the previous evening and had not consumed alcohol or caffeine or smoked until sample collection.

**Results**

The participants’ demographics are shown in Table 1. The plasma H2S levels were significantly lower in patients with type 2 diabetes than in those without (45.1±15.5 μM versus 54.0±26.4 μM, p<0.05; Figure a). All of the patients with type 2 diabetes having poor glycemic control exhibited a progressive reduction in plasma H2S levels as well as HbA1c levels (Figure b). Furthermore, the plasma H2S levels in patients with type 2 diabetes with a history of cardiovascular disease (non-fetal cerebrovascular disease, coronary artery disease, and peripheral artery disease) were significantly lower than those in patients with type 2 diabetes without cardiovascular disease (39.9±13.8 μM versus 47.5±15.9 μM, p<0.01) (Figure c). In the univariate analysis, the plasma H2S levels were negatively correlated with the HbA1c level (γ=-0.730, p<0.001), duration of diabetes (γ=-0.689, p<0.001), systolic blood pressure (γ=-0.203, p<0.05), and diastolic blood pressure (γ=-0.165, p<0.05). A stepwise regression analysis including significant variables was performed. The HbA1c level (β=0.505, p<0.01) was an independent de-
Figure. The plasma H2S levels in patients with and without type 2 diabetes. (a) A comparison of the patients with and without type 2 diabetes. (b) The influence of glycemic control on the plasma H2S levels. (c) The relationship between a history of cardiovascular disease (CVD) and the plasma H2S levels in patients with type 2 diabetes.

Discussion

H2S is the most recent of three endogenously produced molecules to be discovered and termed a gasotransmitter, along with nitric oxide (NO) and carbon monoxide (CO) (11). While initially considered to be toxic, researchers have discovered that these gasotransmitters are endogenously produced at low levels and induce compensatory and protective physiological changes (12). The first gasotransmitter, NO, was discovered in the 18th century but was found in 1987 to be an endogenous vasodilator in mammals through its generation by NO synthase (13). NO is not only a mediator of endothelium-dependent vasodilation but also has anti-inflammatory and antithrombotic effects, as well as an impact on the development of atherosclerosis (14). The second gasotransmitter, CO, is a vital cardiovascular mediator that upregulates the protective mechanisms at a low physiologic concentration (15). The third gasotransmitter, H2S, was found to play an important role in mediating physiological processes. H2S has been shown to modulate the metabolic state, vascular reactivity, and systolic blood pressure (1, 16). The present data demonstrated that plasma H2S levels are significantly reduced in patients with type 2 diabetes, particularly in those with a history of cardiovascular disease. This study is the first report to determine the plasma H2S levels in a large group of Japanese patients with type 2 diabetes.

H2S is an important endogenous vasodilatory intermediate that induces endothelial vasodilation through the KATP channel in vitro and in vivo (17). Type 2 diabetes is likely to be associated with the development of hypertension, hypercholesterolemia, diabetes-related complications, and heart failure (18, 19). However, the precise molecular mechanism underlying why these complications occur in patients with diabetes is still unclear. The current study revealed that plasma H2S levels are reduced in patients with type 2 diabetes.
vascular disease states, including diabetes. H2S is impaired in diabetic mice, and endogenous H2S production may not be entirely accurate because of the interference and artifacts (28). Fluorescent probe detection is another method that could be used for H2S level detection. However, H2S can upregulate the antioxidant protective mechanism (23). These effects of H2S may be salutary to a number of cardiovascular disease states, including diabetes.

Our current study showed that plasma H2S levels negatively correlated with HbA1c, duration of diabetes, and systolic and diastolic blood pressures. The most interesting finding was that glycemic control was the major determinant of the plasma H2S levels, which reflect the HbA1c levels. In addition, Brancaleone et al. reported that biosynthesis of H2S is impaired in diabetic mice, and endogenous H2S production is more impaired in diabetic mice with more severe glycemia than in those with less severe glycemia (6). In our study, the peripheral endothelial function was assessed in 154 type 2 diabetes patients using reactive hyperemia peripheral arterial tonometry (RH-PAT) with an EndoPAT2000 (Itamar Medical, Caesarea, Israel) as described previously (24). The endothelial function was also positively correlated with the plasma H2S levels ($\gamma=0.467$, $p<0.01$). A previous study demonstrated that the plasma H2S levels likely contribute to the endothelium-dependent relaxant function in diabetic rodents (6, 25), which is consistent with our findings for type 2 diabetes patients.

Regarding the possible clinical application of H2S-releasing drugs, H2S exerts a number of cytoprotective and anti-inflammatory effects in many organ systems. A number of H2S-releasing derivatives of existing drugs have been developed and extensively tested in preclinical models (26). H2S-releasing drugs are expected to have the beneficial effects of endogenous gaseous mediators in the gastrointestinal tract, which include reducing the gastrointestinal ulceration and bleeding caused by nonsteroidal anti-inflammatory drugs, as well as in the cardiovascular-protecting systems (27).

Several limitations associated with the present study warrant mention. First, the plasma H2S levels in the present study were measured using the methylene blue assay, which indicates the sulfide concentrations through colorimetry and may not be entirely accurate because of the interference and artifacts (28). Fluorescent probe detection is another method that could be used for H2S level detection. However, H2S catabolism occurs rapidly, which could result in fluctuation of the H2S concentration; therefore, it may be difficult to accurately analyze this important molecule (29). Second, we were unable to assess the endothelial function in all of the type 2 diabetes patients using the EndoPAT2000.

In conclusion, this study showed that the plasma H2S levels are significantly reduced in type 2 diabetes patients, particularly in those with a history of cardiovascular disease. The plasma H2S levels in patients with type 2 diabetes may reflect the HbA1c levels. Further studies are warranted to investigate the relationship between the plasma H2S levels and diabetes and related complications, particularly cardiovascular diseases.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement
The authors would like to thank all of the study participants.

References
1. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935, 2007.
2. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H. Vascular endothelium expresses 3-mercaptopurine sulfurtransferase and produces hydrogen sulfide. J Biochem 146: 623-626, 2009.
3. Módis K, Asimakopoulou A, Coletta C, Papapetropoulos A, Szabo C. Oxidative stress suppresses the cellular bioenergetic effect of the 3-mercaptopurine sulfurtransferase/hydrogen sulfide path-

### Table 2. Univariate and Multivariate Analysis for Association with Each Variable with Hydrogen Sulfide Levels.

| Variable                        | Univariate | Multivariate |
|---------------------------------|------------|--------------|
|                                 | $r$        | $p$ value    | $\beta$ | $p$ value |
| Age (years)                     | -0.069     | 0.387        | -       | -         |
| Body mass index (kg/m²)         | -0.067     | 0.401        | -       | -         |
| HbA1c, % (NGSP)                 | -0.730     | $<0.001$     | -0.505  | 0.001     |
| Fasting glucose per mg/dL      | 0.050      | 0.438        | -       | -         |
| duration of diabetes yrs       | -0.689     | $<0.001$     | 0.006   | 0.937     |
| Systolic Blood Pressure (mmHg) | -0.203     | $<0.05$      | -0.108  | 0.154     |
| Diastolic Blood Pressure (mmHg)| -0.165     | $<0.05$      | -0.090  | 0.311     |
| LDL-C (mg/dL)                   | -0.049     | 0.552        | -       | -         |
| HDL-C (mg/dL)                   | -0.045     | 0.59         | -       | -         |
| Triglyceride (mg/dL)            | 0.128      | 0.08         | -       | -         |
| eGFR (mL/min/1.73m²)           | -0.003     | 0.975        | -       | -         |
| Urinary albumin excretion (µg/g ÷ Cre) | -0.138 | 0.102        | -       | -         |

$R^2 = 0.58$

HbA1c: hemoglobin A1c, eGFR: estimated glomerular filtration rate, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol
way. Biochem Biophys Res Commun 433: 401-407, 2013.
4. Ali MY, Ping CY, Mok YY, et al. Regulation of vascular nitric oxide in vitro and in vivo: a new role for endogenous hydrogen sulfide? Br J Pharmacol 149: 625-634, 2006.
5. Yang G, Sun X, Wang R. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. FASEB J 18: 1782-1784, 2004.
6. Suzuki K, Ohal G, Módis K, et al. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci USA 108: 13829-13834, 2011.
7. Brancaleone V, Roviezzo F, Vellocco V, De Gruttola L, Bucci M, Cirino G. Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol 155: 673-680, 2008.
8. Whiteman M, Gooding KM, Whatmore JL, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 53: 1722-1726, 2010.
9. Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med 13: 488-507, 2009.
10. Ali My, Whiteman M, Low CM, Moore PK. Hydrogen sulfide reduces insulin secretion from HIT-T15 cells by a KATP channel-dependent pathway. J Endocrinol 195: 105-112, 2007.
11. Wang R. Two’s company, three’s a crowd: can H2S be the third? Circ Res 107: 1058-1070, 2010.
12. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol 156: 713-727, 2009.
13. Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 12: 1-13, 2010.
14. Jha S, Calvert JW, Duranski MR, Ramachandran A, Lefer DJ. Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. Am J Physiol Heart Circ Physiol 295: H801-H806, 2008.
15. Fu Z, Liu X, Geng B, Fang L, Tang C. Hydrogen sulfide protects rat lung from ischemia-reperfusion injury. Life Sci 82: 1196-1202, 2008.
16. Fischer CD, Augustine LM, Maher JM, et al. Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos 35: 995-1000, 2007.
17. Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circulation 77: 1337-1344, 2013.
18. Jain SK, Bull R, Rains JL, et al. Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation? Antioxid Redox Signal 12: 1333-1337, 2010.
19. Gemici B, Elsheikh W, Feitosa KB, Costa SK, Muscar A, Wallace JL. H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventive potential. Nitric Oxide 46: 25-31, 2015.
20. Fiorucci S, Santucci L, Distritti E. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 39: 1043-1051, 2007.
21. Nagy P, Pálinkás Z, Nagy A, Budai B, Tóth I, Vasas A. Chemical aspects of hydrogen sulfide measurements in physiological samples. Biochim Biophys Acta 1840: 876-891, 2014.
22. Peng H, Cheng Y, Dai C, et al. A fluorescent probe for fast and quantitative detection of hydrogen sulfide in blood. Angew Chem Int Ed Engl 50: 9672-9675, 2011.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).